Cambridge scientists have created a gel that could end arthritis pain

The sponge material can be loaded with anti -inflammatory drugs that are launched in response to small changes in the pH in the body. During the period of arthritis, the joint becomes inflamed and slightly more acidic than the surrounding tissues.

The materials, developed by researchers at the University of Cambridge, were designed to respond to this natural change in the pH. As the acidity increases, the material becomes softer and more gel -like, which leads to the release of the drug molecules that can be wrapped in its structure.

Since the material is designed for response only within the scope of the narrow pH, the team says that medications can be released specifically where and when they are needed, which may reduce side effects.

If it is used as artificial cartilage in the arthritis, this approach can allow continuous treatment of arthritis, which improves the effectiveness of medications to relieve pain and combat inflammation. Arthritis affects more than 10 million people in the UK, which costs NHS with an estimated £ 10.2 billion annually. Throughout the world, it is capable of affecting more than 600 million people.

While large -scale clinical trials are needed before the material is used in patients, the researchers say their approach can improve results for people with arthritis, and for those who suffer from other cases including cancer. Its results were reported in Journal of the American Chemical Society.

The materials developed by the Cambridge team uses crossed links specially designed and reflected within the polymer network. The sensitivity of these links to changes in acidity levels gives mechanical properties very response.

The material was developed in the research group Professor Orn Sherman in the Chemistry Department of Cambridge. The group specializes in designing and building these unique materials for a set of potential applications.

“For a while now, we were interested in using these materials in the joints, because their properties could mimic the properties of cartilage,” said Sherman, a professor of chemistry above the molecular and polymer and director of Milville Laboratory. “But the combination of this with the highly targeted drug is a truly exciting possibility.”

“These materials can” consider “when there is something wrong in the body and respond by providing treatment when needed. “This can reduce the need for frequent doses of medications, while improving the quality of the patient’s life.”

Unlike many drug delivery systems that require external operators such as heat or light, these systems are operated by body chemistry. The researchers say this can pave the way for the treatment of long -term targeted arthritis that automatically responds to glow, which enhances effectiveness while reducing harmful side effects.

In laboratory tests, the researchers downloaded the material with a fluorescent dye to imitate how a real medicine could behave. They found that at exemplary acidity levels of the joint joint, the material released much more drug shipments compared to the regular and healthy hydrogen figures.

“By controlling the chemistry of these gels, we can make them very sensitive to the exact shifts in the acidity that occurs in the inflamed tissues,” said Dr. Jayed Makon. “This means that the drug is released when needed.”

The researchers say that the approach can be designed for a group of medical conditions, by formulating the chemistry of the material. “It is a very flexible approach,” O’Neill said.

The next steps for the team will include material testing in live systems to assess their performance and safety in a physiological environment. The team says that if it succeeds, their approach can open the door to a new generation of responsive biomard capable of treating chronic diseases with more accurately.

Research has been supported by the European Research Council and the Council of Science and Physical Sciences (EPSRC), a part of the UK research and innovation (UKRI). Orine Sherman, a colleague at Jesus College, Cambridge.